Jes Søgaard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jes Søgaard has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Brian Køster
Department of Prevention and Information, Danish Cancer Society, Copenhagen, Denmark
2 shared publications - Maria Kristine Hagelskær Meyer
Department of Prevention and Information, Danish Cancer Society, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark
2 shared publications - Peter Dalum
Department of Prevention and Information, Danish Cancer Society, Strandboulevarden 49, 2100, Copenhagen Ø, Denmark
2 shared publications - Amnon Lahad
Braun School of Public Health and Community Medicine, Hebrew University of Jerusalem, Jerusalem 91120, Israel
1 shared publication - Brendon Stewart-Freedman
Medical Center, Clalit Health Service, Tel Aviv, Israel
1 shared publication - Daniel Kaminski Rotenberg
The Research Unit for General Practice, Department of Public Health, University of Southern Denmark, Odense, Denmark
1 shared publication
Latest Publications
- Open Access
- 28 February 2022
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 11 (1) , 1-14
Similarities and differences between two well-performing healthcare systems: a comparison between the Israeli and the Danish healthcare systems
Background: Denmark and Israel both have highly rated and well-performing healthcare systems with marked differences in funding and organization of primary healthcare. Although better population health outcomes are seen in Israel, Denmark has a substantially higher healthcare expenditure. This has caused Danish policy makers to take an interest in Israeli community care organization. Consequently, we aim to provide a more detailed insight into differences between the two countries’ healthcare organization and cost, as well as health outcomes. Methods: A comparative analysis combining data from OECD, WHO, and official sources. World Health Organization (WHO) and the Organisation for Economic Co-operation and Development (OECD) statistics were used, and national official sources were procured from the two healthcare systems. Literature searches were performed in areas relevant to expenditure and outcome. Data were compared on health care expenditure and selected outcome measures. Expenditure was presented as purchasing power parity and as percentage of gross domestic product, both with and without adjustment for population age, and both including and excluding long-term care expenditure. Results: Denmark’s healthcare expenditure is higher than Israel’s. However, corrected for age and long-term care the difference diminishes. Life expectancy is lower in Denmark than in Israel, and Israel has a significantly better outcome regarding cancer as well as a lower number of Years of Potential Life Lost. Israelis have a healthier lifestyle, in particular a much lower alcohol consumption. Conclusion: Attempting to correct for what we deemed to be the most important influencing factors, age and different inclusions of long-term care costs, the Israeli healthcare system still seems to be 25% less expensive, compared to the Danish one, and with better health outcomes. This is not necessarily a function of the Israeli healthcare system but may to a great extent be explained by cultural factors, mainly a much lower Israeli alcohol consumption.
- 28 February 2022
- Published by Springer Nature in Israel Journal of Health Policy Research
- Vol. 11 (1) , 1-14
Open AccessSimilarities and differences between two well-performing healthcare systems: a comparison between the Israeli and the Danish healthcare systems
Background: Denmark and Israel both have highly rated and well-performing healthcare systems with marked differences in funding and organization of primary healthcare. Although better population health outcomes are seen in Israel, Denmark has a substantially higher healthcare expenditure. This has caused Danish policy makers to take an interest in Israeli community care organization. Consequently, we aim to provide a more detailed insight into differences between the two countries’ healthcare organization and cost, as well as health outcomes. Methods: A comparative analysis combining data from OECD, WHO, and official sources. World Health Organization (WHO) and the Organisation for Economic Co-operation and Development (OECD) statistics were used, and national official sources were procured from the two healthcare systems. Literature searches were performed in areas relevant to expenditure and outcome. Data were compared on health care expenditure and selected outcome measures. Expenditure was presented as purchasing power parity and as percentage of gross domestic product, both with and without adjustment for population age, and both including and excluding long-term care expenditure. Results: Denmark’s healthcare expenditure is higher than Israel’s. However, corrected for age and long-term care the difference diminishes. Life expectancy is lower in Denmark than in Israel, and Israel has a significantly better outcome regarding cancer as well as a lower number of Years of Potential Life Lost. Israelis have a healthier lifestyle, in particular a much lower alcohol consumption. Conclusion: Attempting to correct for what we deemed to be the most important influencing factors, age and different inclusions of long-term care costs, the Israeli healthcare system still seems to be 25% less expensive, compared to the Danish one, and with better health outcomes. This is not necessarily a function of the Israeli healthcare system but may to a great extent be explained by cultural factors, mainly a much lower Israeli alcohol consumption.
- Open Access
- 5 November 2019
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 4 (3) , 553-554
Correction to: Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
, Results, first sentence, which previously read: “The results were based on a reduction of 9000 skin cancer cases, saving €47 million
- 5 November 2019
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 4 (3) , 553-554
Open AccessCorrection to: Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
, Results, first sentence, which previously read: “The results were based on a reduction of 9000 skin cancer cases, saving €47 million
- Open Access
- 15 October 2019
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 4 (3) , 419-425
Benefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
Background Ninety percent of skin cancers are avoidable. In Denmark, 16,500 cases of melanoma and keratinocyte cancers were registered in 2015. The Danish Sun Safety Campaign has campaigned since 2007, targeting overexposure to ultraviolet radiation. During 2007–2015, the key indicators of skin cancer, i.e. sunbed use and sunburn, showed annual reductions of 6% and 1%, respectively. Objectives We aimed to examine the financial savings to society as a result of the campaign reductions in skin cancer cases (2007–2040), and to examine the campaign’s cost–benefit and return on investment (ROI). Methods The analysis is based on existing data: (1) annual population-based surveys regarding the Danish population’s behavior in the sun; (2) skin cancer projections; (3) relative risks of skin cancers from sunburn and sunbed use and (4) historical cancer incidences, combined with new data; (5) benefits from the avoided costs of skin cancer reductions; and (6) the costs of the Danish Sun Safety Campaign. Results The results were based on a reduction of 9000 skin cancer cases, saving €29 million of which €13 million were derived from sunburn reductions and €16 million from reductions in sunbed use. The ROI was €2.18. Conclusion Skin cancer prevention in Denmark is cost effective. Every Euro spent by the Danish Sun Safety Campaign saved the Danish health budget €2.18 in health expenses.
- 15 October 2019
- Published by Springer Nature in PharmacoEconomics - Open
- Vol. 4 (3) , 419-425
Open AccessBenefit–Cost Analysis of the Danish Sun Safety Campaign 2007–2015: Cost Savings from Sunburn and Sunbed Use Reduction and Derived Skin Cancer Reductions 2007–2040 in the Danish Population
Background Ninety percent of skin cancers are avoidable. In Denmark, 16,500 cases of melanoma and keratinocyte cancers were registered in 2015. The Danish Sun Safety Campaign has campaigned since 2007, targeting overexposure to ultraviolet radiation. During 2007–2015, the key indicators of skin cancer, i.e. sunbed use and sunburn, showed annual reductions of 6% and 1%, respectively. Objectives We aimed to examine the financial savings to society as a result of the campaign reductions in skin cancer cases (2007–2040), and to examine the campaign’s cost–benefit and return on investment (ROI). Methods The analysis is based on existing data: (1) annual population-based surveys regarding the Danish population’s behavior in the sun; (2) skin cancer projections; (3) relative risks of skin cancers from sunburn and sunbed use and (4) historical cancer incidences, combined with new data; (5) benefits from the avoided costs of skin cancer reductions; and (6) the costs of the Danish Sun Safety Campaign. Results The results were based on a reduction of 9000 skin cancer cases, saving €29 million of which €13 million were derived from sunburn reductions and €16 million from reductions in sunbed use. The ROI was €2.18. Conclusion Skin cancer prevention in Denmark is cost effective. Every Euro spent by the Danish Sun Safety Campaign saved the Danish health budget €2.18 in health expenses.